BioSpace Movers & Shakers: Enveda, Evaxion, Elevation
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
Source: biospace.com
Hahn Jun Lee News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Hahn Jun Lee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Hahn Jun Lee Today - Breaking & Trending Today
Health Canada Issues No Objection Letter to Initiate the
PARAMUS, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, Inc. ("Epygenix"), a clinical stage biopharmaceutical company focused on rare and...
Source: globenewswire.com
Polaryx Therapeutics Announces FDA Grants Orphan Drug Designation for PLX-200 in GM2 Gangliosidoses
/PRNewswire/ -- Polaryx Therapeutics, Inc. ("Polaryx"), a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced...
Source: prnewswire.com
Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut Syndrome
/PRNewswire/ -- Epygenix Therapeutics, Inc. ("Epygenix"), a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy,...
Source: prnewswire.com
Journey from Aquarium-to-Bedside to Treat Genetic Epilepsies
May 3, 2021 8:00am Emerging from stealth mode with a pipeline of FDA and EMA Orphan Drug Designation candidates, Epygenix Therapeutics Inc. is poised to become the first biopharmaceutical company to commercialize epilepsy drugs discovered in zebrafish. Epygenix Therapeutics’ six lead drug candidates were identified in a high-throughput phenotype-based drug screening system using a unique zebrafish model developed in the laboratory of Professor Scott C. Baraban, PhD at the University of California, San Francisco (UCSF). Founded in 2016, Epygenix Therapeutics has grown to become a clinical st...
Source: fiercepharma.com